Innocan Pharma Ltd. has released its financial results for the first half of 2025, reporting a 4% decrease in revenues to US$14.8 million, down from US$15.4 million in the same period of 2024. This decline is attributed to market uncertainty and volatility due to global trade tariffs. Gross profit also decreased by 4.9% to US$13.3 million, compared to US$14.0 million in the first half of the previous year. However, the company reported a significant positive shift in operating profit, which increased by 130% to US$0.885 million, a turnaround from an operating loss of US$0.680 million in the first half of 2024. Iris Bincovich, CEO of Innocan, highlighted the company's progress towards listing its Common Shares and Warrants on the Nasdaq Capital Market, which could lead to new opportunities. The company remains focused on its strategic vision, providing opioid-free chronic pain relief solutions for humans and animals, and capitalizing on growth opportunities within its Consumer Wellness segment. Roni Kamhi, CEO of BI Sky Global and COO of Innocan Pharma, expressed confidence in the company's sales execution capabilities and outlined plans for strategic expansion of distribution channels. Innocan's LPT-CBD platform for chronic pain treatment is in late pre-clinical development with promising results from ongoing trials.